FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 精優藥業控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00858 | 說明 | 精優藥業 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.01 ...

Group 1 - The company has issued a total of 160 million new shares at a subscription price of HKD 0.097 per share, with 30 million shares allocated to Subscriber I, 20 million shares to Subscriber II, and 110 million shares to Subscriber III [1] Group 2 - The board has discussed diversifying its business, recognizing that pharmaceuticals and healthcare are core to the "Healthy China 2030" national strategy, benefiting from trends such as an aging population and increasing chronic diseases [2] - The company has a solid foundation in drug production and has shown stable performance in recent years, although international market expansion has faced significant challenges due to varying regulatory requirements [2] - The board sees greater potential in expanding healthcare business overseas, as it typically faces less stringent regulations and faster market entry, particularly in emerging markets with growing middle classes and rising healthcare spending [2] - The new healthcare business is expected to synergize with the company's existing manufacturing infrastructure and distribution network, leveraging the experience of board members in medical devices, diagnostic services, and healthcare investment management [2] - The company plans to strategically allocate approximately 70% of the net proceeds from the share issuance to the startup costs of the new business, including product development, operational expenses, marketing, and pilot projects, while the remaining 30% will be reserved for working capital [2] - This phased strategy aims to systematically establish the healthcare business while maintaining financial flexibility [2]

Group 1 - The company has issued a total of 160 million new shares at a subscription price of HKD 0.097 per share, with specific allocations to three different subscribers [1] - The board has recognized the importance of the pharmaceutical and healthcare sectors in the "Healthy China 2030" national strategy, benefiting from demographic trends such as aging population and increasing prevalence of chronic diseases [2] - The company has a solid foundation in drug production and has shown stable performance in recent years, although international expansion has faced significant challenges due to varying regulatory requirements [2] Group 2 - The board believes that expanding into the healthcare business presents immediate potential, as it typically faces less stringent regulatory pathways and faster market entry [2] - Emerging markets with expanding middle classes and rising healthcare spending are particularly attractive for the company's healthcare products, given local production capacity often falls short [2] - The company plans to strategically allocate approximately 70% of the net proceeds from the share issuance to the startup costs of the new healthcare business, with the remaining 30% reserved for operational funds [2]

格隆汇9月10日丨精优药业(00858.HK)发布公告，认购协议I、认购协议II及认购协议III内载列的所有先 决条件已获达成，而完成I、完成II及完成III均已于2025年9月10日落实。因此，合共1.6亿股新股份(统 称"该等认购股份")已于同日按每股认购股份0.097港元配发及发行。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： 表格類別： 股票 狀態： 新提交 公司名稱： 精優藥業控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期： 2025年9月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 完成根據一般授權發行新股份 董事會欣然宣佈，認購協議I、認購協議II及認購協議III內載列的所有先決條件已獲達成， 而完成I、完成II及完成III均已於二零二五年九月十日落實。因此，合共160,000,000股新股 份（ 統稱「該等認購股份」）已於二零二五年九月十日按每股認購股份0.097港元配發及發行， 其 中 (i) 30,000,000 股 新 股 份 已 發 行 予 認 購 方 I 、 20,000,000 股 新 股 份 已 發 行 予 認 購 方 I I 及 110,000,000股新股份已發行予認購方III（ 統稱「完成」）。 – 1 – 對本公司股權架構的影響 下表顯示(i)緊接完成前；及(ii)緊隨完成後及於本公告日期的股權架構： 完成根據一般授權發行新股份 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00858 | 說明 | 精優藥業 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,390,000,000 | | | | 2,390,000,000 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 2,390,000,000 | | 0 | | 2,390,000,000 | FF301 II. 已發行股份及/或庫存股份變動 公司名稱: 精優藥業控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 二零二五年八月二十二日舉行之股東週年大會 投票表決結果 茲提述精優藥業控股有限公司（「本公司」）日期為二零二五年七月二十九日之通函及股東週 年大會（「股東週年大會」）通告（「該通告」）。 股東週年大會投票表決結果 本公司董事會（「董事會」）宣佈，於二零二五年八月二十二日舉行之股東週年大會上，載於 該通告所有提呈之決議案（「決議案」）均經本公司之股東（「股東」）以投票表決方式獲正式通 過。 於股東週年大會當日，本公司已發行股份（「股份」）總數為2,390,000,000股，此為賦予股東權 利出席股東週年大會並於會上表決贊成或反對決議案的股份總數。概無任何股份給予股東 權利出席股東週年大會但根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.40 條所載須放棄表決贊成決議案。概無任何股東於股東週年大會上須根據上市規則之規定放 棄表決權。 ...

Group 1 - The stock price of Jingyou Pharmaceutical (00858) increased by 20.34% on August 15, reaching HKD 0.142 per share with a trading volume of HKD 6.8024 million [1] - Jingyou Pharmaceutical Holdings Limited primarily promotes and sells pharmaceutical products in the Chinese market, develops gene-related technologies, and works on oral insulin products through joint ventures [1] - The company is listed on the main board of the Hong Kong Stock Exchange and is registered in Bermuda [1] Group 2 - As of the 2024 annual report, Jingyou Pharmaceutical reported total revenue of HKD 51.1515 million and a net profit of HKD 205 million [2]

Group 1 - The core point of the news is that 精优药业 (Jingyou Pharmaceutical) experienced a significant stock price increase of 13.56%, reaching HKD 0.134, with a trading volume of HKD 2.323 million [1] - The company has entered into three subscription agreements on August 14, 2025, with different investors, agreeing to issue a total of 136 million shares at a subscription price of HKD 0.097 per share [1] - The total amounts for the subscription agreements are HKD 291 million for the first agreement, HKD 194 million for the second, and HKD 1.067 billion for the third [1] Group 2 - The net proceeds from the subscription agreements will be used for the potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [2] - The company aims to expand its health-related business opportunities into overseas markets while continuing to utilize its existing internal cash resources to maintain and develop its current pharmaceutical business [2]